BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease.
about
The involvement of BDNF, NGF and GDNF in aging and Alzheimer's diseasePotential therapeutic effects of neurotrophins for acute and chronic neurological diseasesThe relevance of beta-amyloid on markers of Alzheimer's disease in clinically normal individuals and factors that influence these associationsEffect of Estradiol on Neurotrophin Receptors in Basal Forebrain Cholinergic Neurons: Relevance for Alzheimer's DiseaseIdentification of BDNF sensitive electrophysiological markers of synaptic activity and their structural correlates in healthy subjects using a genetic approach utilizing the functional BDNF Val66Met polymorphism.Imago Mundi, Imago AD, Imago ADNIThe pro-domains of neurotrophins, including BDNF, are linked to Alzheimer's disease through a toxic synergy with AβFuture Directions in Imaging Neurodegeneration.Neuroinflammatory challenges compromise neuronal function in the aging brain: Postoperative cognitive delirium and Alzheimer's disease.Ketamine administered pregnant rats impair learning and memory in offspring via the CREB pathway.The evolution of preclinical Alzheimer's disease: implications for prevention trials.Characterizing the role of brain derived neurotrophic factor genetic variation in Alzheimer's disease neurodegenerationEffect of BDNF Val66Met on memory decline and hippocampal atrophy in prodromal Alzheimer's disease: a preliminary study.TrkB reduction exacerbates Alzheimer's disease-like signaling aberrations and memory deficits without affecting β-amyloidosis in 5XFAD mice.Genetic Risk Score Predicts Late-Life Cognitive Impairment.APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease.The effect of resveratrol on beta amyloid-induced memory impairment involves inhibition of phosphodiesterase-4 related signalingEnabling a multidisciplinary approach to the study of ageing and Alzheimer's disease: an update from the Australian Imaging Biomarkers and Lifestyle (AIBL) study.Brain-Derived Neurotrophic Factor in Alzheimer's Disease: Risk, Mechanisms, and Therapy.Genetic epistasis regulates amyloid deposition in resilient aging.The relationship between amyloid deposition, neurodegeneration, and cognitive decline in dementia.BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease.Inhibition of PDE2 reverses beta amyloid induced memory impairment through regulation of PKA/PKG-dependent neuro-inflammatory and apoptotic pathwaysThe BDNF Val66Met polymorphism moderates the effect of cognitive reserve on 36-month cognitive change in healthy older adults.BDNF Val66Met predicts cognitive decline in the Wisconsin Registry for Alzheimer's Prevention.KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ε4-positive cognitively normal adults with high Aβ-amyloid burden.Angelica tenuissima Nakai ameliorates cognitive impairment and promotes neurogenesis in mouse model of Alzheimer's disease.An exercise path to preventing Alzheimer's disease: An Editorial Highlight on 'Exercise and BDNF reduce Ab production by enhancing α-secretase processing of APP'.BDNF Val66Met in preclinical Alzheimer's disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF.Does BDNF Val66Met contribute to preclinical Alzheimer's disease?Acute Down-regulation of BDNF Signaling Does Not Replicate Exacerbated Amyloid-β Levels and Cognitive Impairment Induced by Cholinergic Basal Forebrain Lesion.Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain Aβ-amyloid burden.Dissociable influences of APOE ε4 and polygenic risk of AD dementia on amyloid and cognition.BDNF Polymorphism: A Review of Its Diagnostic and Clinical Relevance in Neurodegenerative Disorders.Impact of brain-derived neurotrophic factor genetic polymorphism on cognition: A systematic review.Val66Met Polymorphism and Gamma Band Disruption in Resting State Brain Functional Connectivity: A Magnetoencephalography Study in Cognitively Intact Older Females
P2860
Q26783362-066C8C8A-3470-4796-8D19-AEDC3AD5C26FQ26827281-75E7E7EC-ECAB-456F-9E5E-697CC3631518Q26830467-0D856A81-09B7-41D8-97F0-0E328130E6C2Q28071845-71643230-BAB8-42D8-B416-0E23ACE6BE4EQ28538189-FCD9BF6E-7404-4B65-B584-90673DDC7214Q28650395-9315FA69-9F20-4D4A-9F44-DEC45E4C3A0AQ30374487-35F73B01-CF7B-4329-9553-CC40EBFDF084Q31162702-381679A6-AE4C-413B-8BFB-D0B94758E5B7Q33745149-55FB1C8B-3573-4AB2-90D3-7E53C58303C8Q33779117-BCCDCEBE-7892-4CDC-BE02-5F9D4AA45417Q34849048-0E75BD68-5FD8-40DF-B07D-EAACE3DE8661Q35006125-56132FCF-D2B9-4E8B-B2FB-12B42E6DC969Q35086470-69276A9E-5E36-4F03-86DB-9A9A7EF657E4Q35753185-F2D2116F-2B76-4B98-8324-C9055CA2F80BQ36031233-39890EC9-6C05-4F29-B64A-70DCEEC73F3AQ36594552-38FA7373-CA6D-4C92-803B-A90345FABC2FQ37109482-FD42B430-9E60-4F76-AE3F-ECF5782A2045Q38178373-A43E6EFD-4CF7-48C7-8BE1-FF06E13D0944Q38263685-ED5F56F5-EDBB-4500-81A8-53F7722D0BD0Q38891562-8CB69139-7F14-4318-A446-2B2D782D2F5DQ39128635-73E8C1F3-9998-4F1B-9EF1-EA5015CF5101Q39493228-C4962334-9CE8-448F-9A5E-35B18AE93E66Q41831293-50DFC1DF-1193-4887-A32C-0EAEFA29B177Q42655796-718860E0-B102-472A-BD52-2293C8909E15Q46093334-7B6FC928-1E18-4074-86CF-5E7C515DDC17Q47549663-355548E2-8A92-44C6-A3F1-F017CA24CE4EQ48018148-69091BE3-7167-4D68-8F13-ECFB150B74A4Q48122774-0A82FE77-EC04-4974-9BA9-9A6AA78F07F6Q48190312-7D21CE3A-AA98-47F6-B7A4-D7634D6628F2Q48495456-7D876D86-F1A1-4D28-8A27-9B74AACFF87BQ50531667-8E0A6C38-FA1F-4D03-9C81-559AEA1D37DAQ51767352-35DE5D68-3928-4102-A128-D337915EF960Q53396798-CCA94FD3-17EC-4A5A-8820-CAA7672F3229Q55092027-F583CAA8-B262-4E47-A302-F6F81AF7CC15Q55690942-7F38ED02-EF6E-4028-B4CB-CD8E6ED70085Q58586784-AC04F1EA-A137-4E4F-9788-A86D7DD10169
P2860
BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease.
@en
BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease.
@nl
type
label
BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease.
@en
BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease.
@nl
prefLabel
BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease.
@en
BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease.
@nl
P2093
P50
P1476
BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease.
@en
P2093
Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group
Christopher C Rowe
David Ames
David Darby
Karra D Harrington
Kathryn A Ellis
Pradeep J Nathan
Ralph N Martins
Robert H Pietrzak
Victor L Villemagne
P304
P356
10.1016/J.NEUROBIOLAGING.2013.05.006
P50
P577
2013-06-12T00:00:00Z